- Home
- COLL vs GPCR Comparison
COLL vs GPCR Comparison
Compare COLL & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- GPCR
- Stock Information
- Founded
- COLL 2002
- GPCR 2016
- Country
- COLL United States
- GPCR United States
- Employees
- COLL N/A
- GPCR N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- GPCR
- Sector
- COLL Health Care
- GPCR
- Exchange
- COLL Nasdaq
- GPCR Nasdaq
- Market Cap
- COLL 958.8M
- GPCR 1.1B
- IPO Year
- COLL 2015
- GPCR 2023
- Fundamental
- Price
- COLL $32.38
- GPCR $19.21
- Analyst Decision
- COLL Strong Buy
- GPCR Strong Buy
- Analyst Count
- COLL 4
- GPCR 7
- Target Price
- COLL $43.75
- GPCR $76.17
- AVG Volume (30 Days)
- COLL 296.7K
- GPCR 719.8K
- Earning Date
- COLL 08-07-2025
- GPCR 08-07-2025
- Dividend Yield
- COLL N/A
- GPCR N/A
- EPS Growth
- COLL N/A
- GPCR N/A
- EPS
- COLL 1.25
- GPCR N/A
- Revenue
- COLL $664,283,000.00
- GPCR N/A
- Revenue This Year
- COLL $20.04
- GPCR N/A
- Revenue Next Year
- COLL $3.98
- GPCR N/A
- P/E Ratio
- COLL $25.18
- GPCR N/A
- Revenue Growth
- COLL 17.17
- GPCR N/A
- 52 Week Low
- COLL $23.23
- GPCR $13.22
- 52 Week High
- COLL $42.29
- GPCR $47.48
- Technical
- Relative Strength Index (RSI)
- COLL 71.18
- GPCR 33.39
- Support Level
- COLL $30.60
- GPCR $18.64
- Resistance Level
- COLL $31.99
- GPCR $23.67
- Average True Range (ATR)
- COLL 0.80
- GPCR 1.17
- MACD
- COLL 0.17
- GPCR -0.22
- Stochastic Oscillator
- COLL 95.50
- GPCR 8.35
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.